OXCARBAZEPINE (oxcarbazepine) by Ichnos Glenmark Innovation is 10-monohydroxy metabolite (mhd) of oxcarbazepine [see clinical pharmacology ()] . Approved for partial-onset seizures in patients 6 years of age, older. First approved in 2007.
Drug data last refreshed 21h ago
10-monohydroxy metabolite (MHD) of oxcarbazepine [see Clinical Pharmacology ()] . The precise mechanism by which oxcarbazepine and MHD exert their anti-seizure effect is unknown; however, in vitro electrophysiological studies indicate that they produce blockade of voltage-sensitive sodium channels,…
Anti-epileptic Agent
Worked on OXCARBAZEPINE at Ichnos Glenmark Innovation? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Oxtellar Extended Release (Oxcarbazepine Extended Release) Patients With Trigeminal Neuralgia
A Study in Participants With Epilepsy, to Evaluate the Pharmacokinetics, Safety and Tolerability of Oxcarbazepine on Padsevonil
Protective Role of Oxcarbazepine in Multiple Sclerosis
Evaluate Retention Rate of Topiramate, Levetiracetam and Oxcarbazepine in a Long-term Epilepsy Treatment
Levetiracetam Versus Oxcarbazepine as Monotherapy to Evaluate Efficacy and Safety in Subjects With Newly or Recently Diagnosed Partial Epilepsy